

Introducing Evaluate CDMO Intelligence for Consulting Firms

**Navigate the complex CDMO landscape.
Position your firm and your firm as
leaders in the market.**

The pharma CDMO market is on an upward trajectory, set to grow at an annualised 7.29% rate out to 2028. As biopharma firms increasingly collaborate with CDMOs, the landscape is ripe with opportunity. Is your consulting firm equipped to harness this growth and keep pace with an evolving industry?

Maintaining a deep understanding of the CDMO landscape is essential. It allows you to expand existing business, secure new clients, and position your firm as a leader in this dynamic field.

Specialised CDMO intelligence is a game-changer that can support your strategic decisions and help you thrive in this competitive market.

This is where Evaluate CDMO Intelligence steps in

Use our time-saving intelligence tool to strategically select the right vendor for your unique needs. Profile and compare CDMOs, accelerate your project timelines, have confidence in your recommendations, and stay ahead of the competition.

HOW WE HELP:



Analyse how your clients stack up against their competition to mitigate threats and capitalise on opportunities.



Easily understand different capabilities of CDMOs and their strengths.



Get up to speed with different manufacturing segments and markets to enhance RFP turnarounds and project deliverables.



Leverage best-in-class intelligence to remove challenging desk research using the public domain and become a trusted advisor in the CDMO space.



Differentiate your firm from other consultancies that conduct manual research.

ONLY EVALUATE EQUIPS YOU TO:



Project revenue with leading drug sales forecasting.



Predict regulatory success through machine learning.



Assess demand with one-of-a-kind drug volume forecasts.

Evaluate
a norstella company

We're here to help you succeed.

Get in touch to discuss how to leverage our best-in-class CDMO Intelligence.

info@evaluate.com | www.evaluate.com

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754